Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Noxxon Pharma AG has 1 pending office action active in the Biotechnology & Pharmaceuticals technology area. Prosecution is distributed across 1 distinct examiner and 1 distinct art unit. This indicates that the company's current patent office interactions are focused on a single examination channel.
VANHORN, ABIGAIL LOUISE is identified as the busiest examiner, with 1 pending office action. This figure matches the total of 1 pending office action for the portfolio, showing that this examiner is responsible for all current prosecution tasks reported.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VANHORN, ABIGAIL LOUISE | 1 | 46.7% | +22.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17844037 | Method of Modulating the Number and the Distribution of Tumor-Infiltrating Leukocytes in Tumors | VANHORN, ABIGAIL LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17844037 | Method of Modulating the Number and the Distribution of Tumor-Infiltrating Leukocytes in Tumors | VANHORN, ABIGAIL LOUISE | 1636 | §102§103§112DP | Final Rejection | — | Pending | Jun 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNoxxon Pharma AG has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Abigail Louise Vanhorn has the most, with 1 of Noxxon Pharma AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.